Skip to content

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

Frank Joseph Palella, Kathleen M. Delaney, Anne C. Moorman, Mark O. Loveless, Jack Fuhrer, Glen A. Satten, Diane J. Aschman, Scott D. Holmberg

New England Journal of Medicine · 1998 · 9,393 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine, 338(13), 853–860. https://doi.org/10.1056/nejm199803263381301

In text: (Palella et al., 1998)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND AND METHODS: National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. RESULTS: Mortality among the patients declined from 29.4 per 100 person-years in the first quarter of 1995 to 8.8 per 100 in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. CONCLUSIONS: The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.

  1. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility2009
  2. Prevention of HIV-1 Infection with Early Antiretroviral Therapy2011
  3. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men2010
  4. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents1998
  5. g_mmpbsa —A GROMACS Tool for High-Throughput MM-PBSA Calculations2014

Metadata from OpenAlex (CC0). Citations are generated from the published record.